Blood pressure control and improved cardiovascular outcomes in the international verapamil SR-trandolapril study

Hypertension

Volumn 50, Issue 2, 2007, Pages 299-305

  Mancia, Giuseppe ^a,f   Messerli, Franz ^b   Bakris, George ^c   Zhou, Qian ^d   Champion, Annette ^d   Pepine, Carl J ^e  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d ABBOTT LABORATORIES   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f SAN GERARDO HOSPITAL   (Italy)

Author keywords

Antihypertensive drugs; Antihypertensive treatment; Blood pressure control; Blood pressure measurement monitoring; Clinical trials; Hypertension

Indexed keywords

TRANDOLAPRIL PLUS VERAPAMIL;

ADVERSE OUTCOME; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION COEFFICIENT; FEMALE; FOLLOW UP; HEALTH VISITOR; HEART INFARCTION; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE;

AGED; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INDOLES; MALE; MIDDLE AGED; PROBABILITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK FACTORS; TREATMENT OUTCOME; VERAPAMIL;

EID: 34547647776     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.090290     Document Type: Article

References (23)

1. Isles CG, Walker LM, Beevers GD, Brown I, Cameron HL, Clarke J, Hawthorne V, Hole D, Lever AF, Robertson JWK, Wapshaw JA. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens. 1986;4:141-156.
2. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004;363:2049 -2051.
3. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-2816.
4. Benetos A, Thomas F, Bean K, Gautier S, Smulyan H, Guize L. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Int Med. 2002;162:577-581.
5. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ. The Collaborative Study Group. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol. 2005;16:2170 -2179.
6. UKPDS 39. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS Study Group. BMJ. 1998;317:713-720.
7. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
8. Bakris GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, Cooper-DeHoff R, Pepine CJ; INVEST Investigators. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension. 2004;44:637-642.
9. Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, MacMahon S, Neal B; PROGRESS Collaborative Group. Lower target blood pressure are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006;24:1201-1208.
10. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials. Lancet. 2003;362:1527-1535.
11. Turnbill F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, Woodward M, MacMahon S; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410-1419.
12. Mancia G, Parati G, Bilo G, Maronati A, Omboni S, Baurecht H, Hennig M, Zanchetti A. Assessment of long term antihypertensive treatment by clinic and ambulatory blood pressure. Data from the ELSA Study. J Hypertens. 2007;25:1087-1094.
13. Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P, Zellig P. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol. 1998;32:1228 -1237.
14. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
15. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler. Thromb. Vasc Biol. 2004;24:e149-e161.
16. Sever PS, Dalhof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet. 2003;361:1149 -1158.
17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ and the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
18. European Society of Hypertension Guidelines Committee. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
19. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens. 2002;4:393- 404.
20. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG for the AASK Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA. 2002;288:2421-2431.
21. Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FH, Margolis KL, Papademetriou V, Probstfield JL, Whelton PK, Habib GB; ALLHAT Collaborative Research Group; ALLHAT Collaborative Research Group. Outcomes in hypertensive black and non-black patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293:1595-1608.
22. Pepine CJ, Kowey PR, Kupfer S, Kolloch RE, Benetos A, Mancia G, Coca A, Cooper-DeHoff R, Handberg E, Gaxiola E, Sleight P, Conti CR, Hewkin A, Tavazzi L. Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Card. 2006;47:547-551.
23. Messerli F, Mancia G, Conti R, Hewkin A, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine C. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Int Med. 2006;144:884-893.